R&D

News

BMS' deucravacitinib psoriasis pill outperforms Amgen's Otez...

Bristol-Myers Squibb could be on the verge of a major coup in psoriasis after its deucravacitinib pill outperformed Amgen’s rival Otezla.

News

Drugs and vaccines may not swiftly end pandemic, says Merck ...

Merck & Co’s CEO Kenneth Frazier has warned that the drugs and vaccines in the pipeline to combat COVID-19 may not be enough to swiftly end the pandemic.

News

UK could get COVID vaccines early in 2021, ahead of other Eu...

COVID-19 vaccines could be approved and available early next year in the UK ahead of other European countries, after its national regulator began its own rolling reviews of shots from Astra

News

Regeneron's COVID-19 antibody cocktail therapy hits safety p...

Regeneron’s coronavirus antibody cocktail therapy against COVID-19, famously used to treat president Donald Trump, has hit a safety issue after independent safety experts recommended it sho

Views & Analysis